SG Americas Securities LLC Raises Holdings in Illumina, Inc. $ILMN

SG Americas Securities LLC lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 31.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 79,893 shares of the life sciences company’s stock after buying an additional 19,165 shares during the quarter. SG Americas Securities LLC owned 0.05% of Illumina worth $10,479,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ILMN. Board of the Pension Protection Fund acquired a new stake in Illumina in the fourth quarter valued at $26,000. Quent Capital LLC purchased a new stake in shares of Illumina during the 3rd quarter worth $29,000. Quarry LP acquired a new position in shares of Illumina during the 3rd quarter worth $32,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Illumina in the 3rd quarter valued at about $33,000. Finally, Strategic Advocates LLC purchased a new position in shares of Illumina in the 3rd quarter valued at about $44,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

ILMN has been the topic of a number of research analyst reports. Stifel Nicolaus boosted their price objective on shares of Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. TD Cowen reaffirmed a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Piper Sandler reduced their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research report on Monday, February 9th. JPMorgan Chase & Co. decreased their price target on Illumina from $130.00 to $120.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Finally, Wall Street Zen upgraded Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. Six equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $129.69.

Illumina Stock Performance

Shares of ILMN opened at $117.67 on Monday. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $155.53. The stock has a market cap of $17.99 billion, a price-to-earnings ratio of 21.59, a price-to-earnings-growth ratio of 2.25 and a beta of 1.45. The firm has a 50 day simple moving average of $128.81 and a 200-day simple moving average of $121.87.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.Illumina’s revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Activity

In related news, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the sale, the senior vice president owned 16,321 shares of the company’s stock, valued at $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.60% of the stock is owned by corporate insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.